"id","uuid:ID","instanceType","rationale","versionIdentifier"
"StudyVersion_1","e508aae4-6e5e-4224-a479-b39d7bd46876","StudyVersion","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","2"
